First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: Factors predicting fibrotic evolution.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 25 05 2020
revised: 16 08 2020
accepted: 19 08 2020
pubmed: 26 8 2020
medline: 29 10 2020
entrez: 26 8 2020
Statut: ppublish

Résumé

At the end of February, the Lombardy region (Northern Italy) was involved in the pandemic spread of the new COVID-19. We here summarize the clinical and radiological characteristics of 90 confirmed cases and analyze their role in predicting the evolution of fibrosis. We retrospectively analyzed the clinical and radiological data of 90 patients with COVID-19 pneumonitis. All subjects underwent an HRCT study on the day of admission and eight weeks later, and were treated with lopinavir + ritonavir (Kaletra) 400/100 mg two times a day or darunavir + ritonavir two times a day, and Hydroxychloroquine 200 mg two times a day. Pulmonary fibrosis was defined according to the Fleischner Society glossary of terms for thoracic imaging. Twenty-three patients developed pulmonary fibrosis (25.5%): 15 were males, whose mean age was 75 ± 15. The majority were active smokers (60.8%) and had comorbidities (78.2%), above all, hypertension (47.8%), and diabetes (34.7%). Interestingly, in our series of cases, the "reversed halo sign" is frequent (63%) and seems to be a typical COVID-19 pneumonitis pattern. The patients showing fibrosis had a higher grade of systemic inflammation (ESR and PCR) and appeared to have bone marrow inhibition with a significant reduction in platelets, leukocytes, and hemoglobin. To conclude, our data showed that the reversed halo sign associated with a ground-glass pattern may be a typical HRCT pattern of COVID-19 pneumonitis. The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement.

Sections du résumé

BACKGROUND BACKGROUND
At the end of February, the Lombardy region (Northern Italy) was involved in the pandemic spread of the new COVID-19. We here summarize the clinical and radiological characteristics of 90 confirmed cases and analyze their role in predicting the evolution of fibrosis.
METHODS METHODS
We retrospectively analyzed the clinical and radiological data of 90 patients with COVID-19 pneumonitis. All subjects underwent an HRCT study on the day of admission and eight weeks later, and were treated with lopinavir + ritonavir (Kaletra) 400/100 mg two times a day or darunavir + ritonavir two times a day, and Hydroxychloroquine 200 mg two times a day. Pulmonary fibrosis was defined according to the Fleischner Society glossary of terms for thoracic imaging.
RESULTS RESULTS
Twenty-three patients developed pulmonary fibrosis (25.5%): 15 were males, whose mean age was 75 ± 15. The majority were active smokers (60.8%) and had comorbidities (78.2%), above all, hypertension (47.8%), and diabetes (34.7%). Interestingly, in our series of cases, the "reversed halo sign" is frequent (63%) and seems to be a typical COVID-19 pneumonitis pattern. The patients showing fibrosis had a higher grade of systemic inflammation (ESR and PCR) and appeared to have bone marrow inhibition with a significant reduction in platelets, leukocytes, and hemoglobin.
CONCLUSIONS CONCLUSIONS
To conclude, our data showed that the reversed halo sign associated with a ground-glass pattern may be a typical HRCT pattern of COVID-19 pneumonitis. The evolution to pulmonary fibrosis is frequent in older males and patients with comorbidities and bone marrow involvement.

Identifiants

pubmed: 32841688
pii: S1201-9712(20)30683-4
doi: 10.1016/j.ijid.2020.08.054
pmc: PMC7443096
pii:
doi:

Substances chimiques

Antiviral Agents 0
Drug Combinations 0
lopinavir-ritonavir drug combination 0
Lopinavir 2494G1JF75
Hydroxychloroquine 4QWG6N8QKH
Ritonavir O3J8G9O825

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

485-488

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Aging (Albany NY). 2020 Apr 10;12(7):6037-6048
pubmed: 32275643
J Thorac Imaging. 2020 Jul;35(4):W87-W89
pubmed: 32404798
Invest Radiol. 2020 Jun;55(6):332-339
pubmed: 32134800
Invest Radiol. 2020 May;55(5):257-261
pubmed: 32091414
Eur Radiol. 2020 Oct;30(10):5455-5462
pubmed: 32367422
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Intern Med. 2020 Aug;288(2):192-206
pubmed: 32348588
Eur Radiol. 2020 Aug;30(8):4381-4389
pubmed: 32193638
AJR Am J Roentgenol. 2020 Jul;215(1):87-93
pubmed: 32174129
Lancet Respir Med. 2018 Feb;6(2):138-153
pubmed: 29154106

Auteurs

Maurizio Marvisi (M)

Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy. Electronic address: mmarvis@alice.it.

Francesco Ferrozzi (F)

Dept. of Radiology, Istituto Figlie di San Camillo, Cremona, Italy.

Laura Balzarini (L)

Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy.

Chiara Mancini (C)

Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy.

Sara Ramponi (S)

Dept. of Internal Medicine and Pneumology, Istituto Figlie di San Camillo, Cremona, Italy.

Mario Uccelli (M)

Dept. of Radiology, Istituto Figlie di San Camillo, Cremona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH